Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$13.07 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)370.57K
Market Cap
$184.32M
Enterprise Value-$22.00M
Total Cash (Recent Filing)$207.64M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 11, 2026EPS Estimate
-2.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.98
Shares Outstanding13,405,401
10 Day Avg. Volume487,731
30 Day Avg. Volume370,568
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-1.68
Enterprise Value/Gross Profit-3.40
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$51.00Price Target Upside238.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.66
Revenue Forecast (FY)$89.70M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross Margin ImprovementMaterial margin improvement alongside revenue growth indicates improving unit economics and product/service mix. If sustained, higher gross margins provide a clearer path to scalable profitability as clinical programs translate into commercial or partnered revenues, reducing the gap between sales and R&D/fixed costs over time.
Conservative Balance Sheet / Low LeverageSignificantly stronger equity and low debt increase financial flexibility to fund R&D, pursue strategic partnerships, and survive clinical development cycles without onerous interest burdens. A larger capital base reduces near-term refinancing risk and supports optionality for development and regulatory milestones.
Clinical Validation: TONMYA Phase 3Robust Phase 3 efficacy and favorable benefit-risk metrics materially de-risk the lead program. Positive pivotal data improve prospects for regulatory approval, commercial licensing or partner interest, and create a durable value driver that can unlock milestone payments or revenue if translated into approvals and market access.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained large cash burn from operations forces continuous financing needs and constrains strategic flexibility. Without a shift to positive cash generation or material partnering, ongoing negative FCF increases dilution risk and may limit the company's ability to complete expensive late-stage trials or expand commercialization efforts.
Deep Operating Losses And Negative EBITDAVery large operating losses reflect a cost base far exceeding current revenue and indicate the company remains years from self-sustaining profitability. Continued negative operating leverage reduces resilience to development setbacks and means value creation depends heavily on successful clinical outcomes or accretive partnerships.
Reliance On Equity FinancingsRegular equity raises signal dependence on dilutive capital to fund operations. Terms like ownership caps, lock-ups and placement fees increase financing costs and can dilute existing shareholders, potentially limiting long-term shareholder alignment and signaling that internal cash generation is insufficient for planned development timelines.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $13.07 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $184.32M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 45 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported -$3.98 earnings per share for the quarter, missing the consensus estimate of -$3.19 by -$0.79.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.58.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 13,405,401 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$3.98 in its last earnings report, missing expectations of -$3.19. Following the earnings report the stock price went down -1.268%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (238.20% Upside)
$51.00 (238.20% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $223.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.19%
12-Months-Change
Fundamentals
Return on Equity
-60.15%
Trailing 12-Months
Asset Growth
70.16%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$51.00
▲(238.20% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
6.28% Mutual Funds
0.78% Other Institutional Investors
84.87% Public Companies and
Individual Investors